CGEN

#3025
Compugen Ltd. - Ordinary Shares
2.6 3 USD
-5.40%
Setor: Cuidados de saúde
Base: USD
Moeda do lucro: USD
Faixa diária
2.63
2.63
Faixa anual
1.32
3.24
Mudança diária
-5.40%
Mudança mensal
+0.38%
Mudança em 6 meses
+67.52%
Mudança anual
+69.68%
Fechamento anterior
2.7 8
Open
2.6 3
Mínimo
2.6 3
High
2.6 3
Volume
11
Abrir gráfico completo Full chart

Financials

Visão geral Relatórios Estatísticas
Trimestral Ano
  • Market Capitalization 248.67 M
  • Employee 75
  • Founded 1993
  • CEO Anat Cohen-Dayag
  • Website www.cgen.com
  • Headquarter Israel
  • FIGI UNKNOWN
  • Industry Biotecnologia
Receita total
Lucro líquido
Lucro básico por ação
Dívida total
Fluxo de caixa livre
Caixa e equivalentes de caixa
Índice preço/lucro
4.03
Índice preço/fluxo de caixa
1.97

Compugen Ltd. - Ordinary Shares

Compugen Ltd. is a clinical-stage publicly traded predictive drug discovery and development company headquartered in Israel, with shares traded on the NASDAQ Capital Market and on the Tel Aviv Stock Exchange. Compugen was established as computational drug discovery service provider in 1993. Compugen originally acted as service provider for pharma companies, supplying its software and computational services to predict different types of biological phenomena. It had arrangements with big companies such as Novartis AG, Abbot Laboratories and Pfizer Inc. Subsequently, Compugen made a decision to become a drug development company with its own internal pipeline, and in 2010, decided to a focus on oncology and immunology. OncoMed Pharmaceuticals and Five Prime Therapeutics are among Compugen's competitors.

Notícias